table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 mild to moderate
potential COVID-19 treatments
adjuvant therapies
anticoagulant X-COVID-19
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
clarithromycine Rashad ...
colchicine COL-COVID ...
non-steroidal anti-inflammatory drugs Guzman-Esquivel
Indomethacin Ravichandran
Immunostimulants drugs
convalescent plasma treatment Libster PLACID
interferon
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
interferon / TFF2 Fu
peginterferon Jagannathan
PNB001 Lattmann
neutralizing antibody
casirivimab/imdevimab (Ronapreve) Somersan-Karakaya ...
Immunosuppressants drugs
anakinra CORIMUNO-ANA-1
janus kinase (JAK) inhibitor
tofacitinib Murugesan
lenzilumab LIVE-AIR ...
Kinase inhibitors
imatinib Covid-19 HUF
antiandrogenic
progesterone Ghandehari
antiviral and associated therapy
azithromycin Rashad A ... COALITION I Covid-19 Brazil ...
azvudine Ren
bromhexine Li T
chloroquine and derivatives
chloroquine NCT04342650
hydroxychloroquine Zhaowei Chen Coalition Covid-19 Brazil I ... NCT04333654 Dubee HC-nCoV ... FACCT Trial Kamran
Ensitrelvir (XOCOVA) Mukae - Phase 2a
favipiravir Udwadia AVIFAVIR Shenoy S Solaymani-Dodaran NCT04542694 Holubar M Dabbous HM IRCT20151227025726N14 // U07 Ruzhentsova T FACCT Trial Shinkai
favipiravir plus interferon Khamis
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine Coalition Covid-19 Brazil I ...
ivermectin Shahbaznejad Ahmed Abd-Elsalam Chachar Bukhari Krolewiecki Chaccour Kirti Babalola I-TECH ... RIVET-COV ... Mayer
ivermectin plus doxycycline NCT04523831 ...
lopinavir/ritonavir ELACOI ...
lopinavir/ritonavir, ribavirin and interferon beta-1b Hung et al.
nitazoxanide Silva Rocco Fontanesi
remdesivir GS-US-540-5773 ... GS-US-540-5774, 10 days GS-US-540-5774, 5 days
sofosbuvir and ledipasvir Nourian A
umifenovir (arbidol) Yethindra ELACOI ...
miscellaneous
Cannabidiol Crippa ...
sabizabulin VERU-111
Renin-angiotensin-system-acting agents
discontinuation of ACEI/ARB Lopes ...
Vitamins
Vitamin D Rastogi
hight dose vitamin D COVIT-TRIAL

60 studies excluded by filtering options 1

5092 Yang, 2020 1133not a RCThigh risk of bias
5228 Bean, 2020 1193not a RCThigh risk of bias
5295 Zhang, 2020 1133not a RCThigh risk of bias
5331 Li, 2020 1134not a RCThigh risk of bias
5332 Meng, 2020 1134not a RCThigh risk of bias
5345 Yan et al., 2020 1204not a RCThigh risk of bias
5346 Mancia, 2020 1203not a RCThigh risk of bias
5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5348 Reynolds (COVID positive patient), 2020 1133not a RCThigh risk of bias
5349 Reynolds (prophylaxis), 2020 1133not a RCThigh risk of bias
5370 Khera (outpatients), 2020 1133not a RCThigh risk of bias
5372 Khera (inpatients), 2020 1133not a RCThigh risk of bias
5399 Northwell Consortium (Richardson), 2020 0990selection pending
5440 Morales, 2020 1130not a RCTrisk of bias not avaialble
5604 Schneeweiss, 0 0130selection pending
5605 Vila-Corcole, 0 0130selection pending
5619 Pan, 2020 0130selection pending
5797 Rossi, 0 0130selection pending
5903 Anzola, 2020 0100selection pending
6660 Bae, 2021 0120selection pending
6729 Shah, 2021 1133not a RCThigh risk of bias
6788 Waissengrin, 2021 0130selection pending
6790 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6894 Andrejko, 2021 1200not a RCTrisk of bias not avaialble
6927 Rossman, 2021 0130selection pending
6931 Yair, 2921 1320not a RCTrisk of bias not avaialble
6934 Boyarsky, 2021 1320not a RCTrisk of bias not avaialble
6949 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6981 Public Health England (Harris), 2021 1133not a RCThigh risk of bias
7025 Haberman, 2021 0130selection pending
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7325 Skowronski, 2021 0130selection pending
7419 Scotland delta (Sheikh), 2021 1203not a RCThigh risk of bias
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
7950 Harris, 2021 1133not a RCThigh risk of bias
8143 Butt, 2021 1202not a RCT
8147 Canada (Nasreen), 2021 1202not a RCT
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8150 Ramasamy, 2021 0320selection pending
8164 Public Health England, May 16, 2021 (Bernal), 2021 1202not a RCT
8255 REACT-SCOT, 2021 1200not a RCTrisk of bias not avaialble
8272 Martinez-Baz, 2021 1130not a RCTrisk of bias not avaialble
8274 REACT-1 round 13 final report (Elliott, Imperial College London), 2021 1133not a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8294 CDC Mesa County, Colorado, 2021 1133not a RCThigh risk of bias
8313 Bahl (Fully vaccinated vs unvaccinated), 2021 0100selection pending
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8359 Oxford (Pouwels), 2021 1132not a RCT
8360 HEROES-RECOVER (Fowlkes), 2021 1133not a RCThigh risk of bias
8513 Grannis, 2021 1203not a RCThigh risk of bias
8514 VA (Bajema), 2021 1203not a RCThigh risk of bias
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9216 Sultan, 2022 0120selection pending
9267 Ostropolets, 2021 0120selection pending
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble
9491 Li X, 2022 1120not a RCTrisk of bias not avaialble
9590 UKHSA report week 12 (24 March 2022), 2022 1120not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons